Publish in this journal
Journal Information
Vol. 17. Issue 4.
Pages 207-211 (April 2021)
Share
Share
Download PDF
More article options
ePub
Visits
...
Vol. 17. Issue 4.
Pages 207-211 (April 2021)
Original Article
DOI: 10.1016/j.reumae.2019.05.006
Development of a risk indicator score for the identification of interstitial lung disease in patients with rheumatoid arthritis
Desarrollo de una regla de predicción clínica para identificar enfermedad pulmonar intersticial en pacientes con artritis reumatoidea
Visits
...
Francisco Paulina,b,
Corresponding author
francisco_paulin@yahoo.com.ar

Corresponding author.
, Tracy Jennifer Doylec, Juan Francisco Mercadod, Leandro Fassolaa, Martín Fernándeza, Fabián Caroa, María Laura Albertia, María Elena Crespo Espíndolae, Emilio Buschiazzoe
a Hospital María Ferrer, Buenos Aires, Argentina
b Hospital Juan A. Fernández, Buenos Aires, Argentina
c Brigham and Women's Hospital, Boston, USA
d UPMC, PA, USA
e Hospital Señor del Milagro, Salta, Argentina
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (2)
Table 1. Demographic and Clinical Characteristics of RA Patients With and Without ILD.
Table 2. Univariate and Multivariate Logistic Regression Analysis With the Presence of ILD as Dependent Variable in Patients With RA.
Show moreShow less
Abstract
Background

Clinically evident interstitial lung disease (ILD) affects 10%–42% of RA patients with prognostic implications. The aim of this study was to discern which factors are associated with the presence of ILD in RA patients and to develop a score that could help to stratify the risk of having ILD in RA patients.

Methods

Case–control study. We included RA patients recruited from ILD and rheumatology clinics. We retrieved the following data: gender, age, presence of extra articular manifestations, disease activity scores, antibodies status, ESR, and medication use. Multivariate logistic regression was performed. A risk indicator score was developed.

Results

Of 118 patients included in this study, 52 (44%) had RA-ILD (cases) and 66 (56%) had RA without ILD (controls). Twenty-six patients were male (22%), the mean age was 56.6±15.6 years. Five variables were significantly associated with the presence of ILD: male gender, smoking, extraarticular manifestations, a CDAI score>28, and ESR>80mm/h. The AUC of the final model curve was 0.86 (95%CI 0.79–0.92). Two potential cut-off points of the risk indicator score were chosen: a value of 2 points showed a sensitivity of 90.38% and a specificity of 63.64%, while a value of 4 points showed a sensitivity of 51.9% and a specificity of 90.9%.

Conclusion

This study identified risk factors that could help identify which RA patients are at risk of having ILD through the development of a risk indicator score. This score needs to be validated in an independent cohort.

Keywords:
Rheumatoid arthritis
Interstitial lung disease
Risk indicator score
Pulmonary fibrosis
Resumen
Introducción

La enfermedad pulmonar intersticial (EPI) clínicamente evidente afecta al 10-42% de los pacientes con Artritis Reumatoidea (AR), con impacto en el pronóstico. El objetivo de este estudio fue identificar factores asociados y desarrollar una regla para estratificar el riesgo de EPI en pacientes con AR.

Métodos

Estudio de casos y controles. Se incluyeron pacientes con AR de una clínica de enfermedades intersticiales y un servicio de reumatología. Se consignaron datos demográficos, manifestaciones extraarticulares, scores de actividad de la enfermedad, autoanticuerpos, tratamiento. Se analizó con regresión logística multivariada.

Resultados

Se incluyeron 118 pacientes con AR, 52 (44%) con EPI (casos) y 66 (56%) sin EPI (controles). Veintiséis (22%) hombres, media de edad 56±15.6 años. Cinco variables se asociaron significativamente con la presencia de EPI: género masculino, tabaquismo, manifestaciones extraarticulares, CDAI> 28, y eritrosedimentación> 80mm/h. El área bajo la curva del modelo final fue 0.86 (IC 95% 0.79-0.92). Se escogieron dos potenciales puntos de corte del score: 2 puntos con una sensibilidad del 90.38% y una especificidad del 63.64%, y 4 puntos con una sensibilidad del 51.9% y una especificidad del 90.9%.

Conclusión

Nuestro estudio identificó variables que podrían ayudar a identificar que pacientes con AR se encuentran en riesgo de presentar EPI.

Palabras clave:
Artritis reumatoidea
Enfermedad pulmonar intersticial
Score de riesgo
Fibrosis pulmonar

Article

These are the options to access the full texts of the publication Reumatología Clínica (English Edition)
Member
If you are member of Sociedad Española de Reumatología (SER) or the Colegio Mexicano de Reumatología (CMR):
Please go to the member area of SER or CMR and log in.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Reumatología Clínica (English Edition)

Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Precio 19,34 €

Comprar ahora
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Idiomas
Reumatología Clínica (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?